<DOC>
	<DOCNO>NCT01873469</DOCNO>
	<brief_summary>Local recurrence major problem clinical treatment glioblastoma multiforme ( GBM ) . Today sensitive imaging method detect glioblastoma [ 11C ] MET Positron emission tomography ( PET ) , patient also tumour manifestation detect visible MRI investigation . The aim study investigate association high [ 11C ] MET tracer uptake postoperative radiochemotherapy concurrent temozolomide ( TMZ ) time recurrence patient glioblastoma multiforme . Also site recurrence correlate [ 11C ] MET image early radiochemotherapy . All image information include treatment planning treatment decision . The study provide basis later radiation dose escalation trial base [ 11C ] MET imaging .</brief_summary>
	<brief_title>Impact 11C-Methionine PET/MRI Individual Tailoring Postoperative Radiochemotherapy Glioblastoma Multiforme</brief_title>
	<detailed_description>The current study aim investigate association high [ 11C ] MET tracer uptake postoperative radiochemotherapy concurrent temozolomide ( TMZ ) time recurrence patient glioblastoma multiforme ( GBM ) . [ 11C ] MET-PET expect provide diagnostic ( quantitative spatial information ) well prognostic information , monitor treatment , help stratification patient radiotherapeutic intervention dose-painting order optimize clinical application potentially improve treatment outcome . This study aim provide basis ( e.g . optimal threshold value , sensitivity , specificity MET uptake ) late intervention trial treatment intensification , e.g . proton boost irradiation base specific biomarkers . The trial one-arm single-center , non-randomized observational ( biomarker ) study . After resection biopsy , patient newly diagnose glioblastoma multiforme receive [ 11C ] MET-PET/MRI scan start concurrent radiochemotherapy ( ~1-4 week surgery ) . A fusion planning CT irradiation treatment planning perform . Postoperative radiotherapy apply daily fraction 2 Gy give 5 day per week 6 week , total dose 60 Gy ( 50 Gy boost 10 Gy ) , concomitant administration daily Temozolomide ( 75 mg/m2 p.o . ) 1st day last day radiotherapy . Follow [ 11C ] MET-PET/MRI perform every 3 month recurrence death patient . The uptake [ 11C ] MET-PET ( standard uptake value - SUV ) tumour normal contralateral grey matter start concurrent radiochemotherapy determine . For tumour , ratio tracer uptake tumor contralateral gray matter calculate ( lesion-to-gray matter ratio [ l/g ] ) . Primary end point time recurrence ( TTR ) function [ 11C ] MET uptake chemoradiotherapy . Secondary endpoint overall survival ; toxicity ; C-Index/ROC curve ( sensitivity , specificity , optimal threshold normal/tumour tissue index ) , necrosis rate ; site recurrence . The primary analysis use Cox proportional hazard model establish linear association [ 11C ] -MET time-to-recurrence use one-sided alpha = 0.1 . Parallel translational study orthotopic GBM xenograft ( generated patient material trial ) nude mouse perform laboratory evaluate [ 11C ] MET-PET tool tailor high precision radiotherapy . Histological , biological genetic study plan validate image find explore underlying mechanism .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>histologically confirm newly diagnose glioblastoma multiforme macroscopic total tumour resection biopsy indication combine radiochemotherapy temozolomide patient allow take part clinical trial time begin radiochemotherapy later 7 week surgery Karnofsky Performance Score ≥ 60 , ECOG ≤2 woman childbearing potential , ( men ) adequate contraception ability subject understand character individual consequence clinical trial write informed consent previous radiotherapy brain chemotherapy TMZ radiochemotherapy time interval &gt; 7 week surgery begin radiochemotherapy patient suitable radiochemotherapy know malignant disease impact prognosis patient and/or likely require treatment interfere study therapy pregnant lactating woman patient nonMRI compatible metal implant , pacemaker nonMRI compatible external automatic defibrillator , insulin pump , neurostimulators , cochlear implant Claustrophobic patient refusal patient take part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>radiotherapy</keyword>
</DOC>